Atopic Dermatitis (AD)

77 clinical trials · Condition

Record	Firm	Date
Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children (NCT06361992)	Catalysis SL	2022-03-15
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis (NCT07182864)	Minghui Pharmaceutical (Hangzhou) Ltd	2022-01-06
Clinical Trial to Evaluate the Efficacy and Safety of an Ozonated Oil in Atopic Dermatitis (NCT07744516)	Laboratorios Ozoaqua	2021-09-22
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis (NCT04541810)	AbbVie	2021-01-26
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil (NCT04666675)	AbbVie	2020-12-24
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects (NCT04056130)	KoBioLabs	2019-10-04
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy (NCT04173442)	Regeneron Pharmaceuticals	2018-10-24
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis (NCT03389893)	National Institute of Allergy and Infectious Diseases (NIAID)	2018-07-25
Atopic Dermatitis (AD) and Food Allergy (NCT03168113)	National Institute of Allergy and Infectious Diseases (NIAID)	2017-06-12
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema (NCT02357940)	Johnson & Johnson Consumer Inc. (J&JCI)	2015-01-01
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) (NCT01979016)	Regeneron Pharmaceuticals	2013-12-31

Track Atopic Dermatitis (AD) automatically

Every clearance here is in the API, with alerts when new ones post.